| INTRODUCTION
Cystic fibrosis (CF) is a life-threatening autosomal recessive disorder caused by severely impaired or absent function of the cystic fibrosis transmembrane regulator (CFTR), a protein that normally functions as an anion channel transporting bicarbonate and chloride across epithelial membranes. 1 Loss of CFTR function results in multi-organ dysfunction with
(1) exocrine pancreatic insufficiency typically commencing in infancy and leading to malabsorption and failure to thrive and (2) impaired respiratory secretion clearance and pulmonary inflammation contributing to susceptibility to sinopulmonary infections, progressive decline in lung function, and ultimately respiratory failure. With advances in CF nutrition and pulmonary care improving median survival well in to adulthood, cystic fibrosis-related diabetes (CFRD) has emerged as a common comorbidity affecting~40% of adults with CF by age 30 years. 2 This increased diabetes risk is more pronounced in the setting of pancreatic insufficiency, 3 a finding suggested by the ability of CF patients with preserved pancreatic exocrine function to maintain normal β-cell secretory capacity relative to an impairment seen in those with pancreatic insufficiency. 4 Highlighting its clinical relevance, CFRD is associated with deterioration in nutritional status, decline in pulmonary function, and increased mortality, which occurs despite early identification and treatment. 5 Identification of patients with pancreatic insufficient CF (PI-CF) at high-risk of CFRD is critically important to developing therapeutic measures aimed at preserving β-cell function. Current criteria for evaluating glucose tolerance in CF acknowledge early glucose abnormalities and specify an isolated 1-hour glucose during oral glucose tolerance testing (OGTT) ≥200 mg/dL (11.1 mmol/L) as abnormal. 6 We have recently reported impaired β-cell secretory capacity even in the setting of PI-CF and normal glucose tolerance (NGT), defined using the 1-hour OGTT glucose <200 mg/dL, compared to pancreatic sufficient CF (PS-CF) and healthy control subjects. 4 In non-CF populations, 1-hour OGTT glucose above a threshold as low as 155 mg/dL (8.6 mmol/L) portends increased risk of developing type 2 diabetes, [7] [8] [9] [10] [11] [12] greater adverse cardiovascular disease outcomes, 7, 13 and increased mortality, 7, 14 and is associated with impaired β-cell function. 15, 16 In CF, higher 1-hour glucose is associated with a 4-to-5-fold increased risk for developing CFRD over the subsequent 5 years. 17 Thus, improved discrimination of OGTT 1-hour glucose that identifies early defects in insulin secretion is needed to better understand the relationships between glucose intolerance and CFrelevant outcomes, and for developing interventions that may preserve pancreatic β-cell function and interrupt the progression to CFRD.
Based on these observations in non-CF and CF populations with elevated 1-hour OGTT, we hypothesized that the presence of 1-hour OGTT glucose ≥155 mg/dL in PI-CF would be associated with impaired early-phase insulin secretion during meal ingestion and impaired β-cell secretory capacity compared to PI-CF individuals with 1-hour OGTT glucose <155 mg/dL.
| SUBJECTS AND METHODS

| Subjects
Adolescents age ≥16 years and adults with a confirmed diagnosis of PI-CF, including positive sweat test or CFTR mutation analysis, and requirement for pancreatic enzyme replacement therapy, 18 were invited to participate. Glucose tolerance was defined by fasting, 1-, and 
| Mixed-meal tolerance test
A standardized mixed-meal tolerance test (MMTT) was performed to assess post-prandial glucose tolerance and insulin secretion as previously described. 4 After a 12-hour overnight fast, an antecubital or 
| Glucose-potentiated arginine test
The glucose-potentiated arginine (GPA) test was performed to assess β-cell secretory capacity and demand as previously described. 4, 21, 22 After a 12-hour overnight fast, 1 catheter was placed in an antecubital vein for infusions, and 1 catheter was placed in a distal forearm or hand vein for blood sampling, with the hand placed in a heating pad to promote arterialization of the venous blood. After at least 20 minutes acclimatization to the catheters, baseline blood samples were taken at t = −5 and −1 minute before injection of 5 g of 10% arginine over 1-minute starting at t = 0. Additional blood samples were collected at t = 2, 3, 4, and 5 minutes after arginine injection. Beginning at t = 10 minutes, a hyperglycemic clamp technique 23 using a variable rate infusion of 20% dextrose was performed to achieve a plasma glucose concentration of~230 mg/dL (~13 mmol/L). Blood samples were taken for every 5 minutes to adjust the infusion rate and achieve the desired plasma glucose concentration. After 45 minutes of glucose infusion (at t = 55 minutes), a second 5-g arginine pulse was injected with identical blood sampling. A subsequent 2-hour period without glucose infusion allowed plasma glucose to return to the baseline. A second hyperglycemic clamp was then performed to achieve a plasma glucose concentration of~340 mg/dL (~19 mmol/L). After 45 minutes of glucose infusion, a third 5-g arginine pulse was injected with identical blood sampling. PRECISE Center, University of Pennsylvania, Philadelphia, Pennsylvania). CV for glucose was calculated from the glucose SD divided by mean glucose.
| Biochemical analysis
| Mixed-meal tolerance test
Insulin secretory rates (ISRs) were calculated from C-peptide values and derived by parametric deconvolution of C-peptide kinetics using a two-compartment model 25 
| Statistical analyses
The study was designed as a pilot powered to detect differences in β-cell secretory capacity between groups assuming a weighted SD 1/3 of the mean 27 and requiring~10 subjects per group to provide 80% power. Data are reported as median and interquartile range, unless otherwise noted. Subject demographics were examined using the Kruskal-Wallis test for continuous variables and χ 2 test for categorical variables. Comparison of results across study groups was performed with the nonparametric test for progressively worsening differences across ordered groups, nptrend, and when significant differences at P < .05 were found, pairwise comparisons were performed using the Mann-Whitney U test. Spearman correlation was performed to examine the relationship of PISRs and 1-hour OGTT glucose. All analyses were performed using STATA 12 (StataCorp LP).
Significance was considered at P ≤ .05 (two-tailed).
3 | RESULTS
| Subject characteristics
Forty-two subjects with CF participated in the study: 13 PI-NGT, 13 PI-EGI, 8 PI-IGT, and 8 CFRD ( Table 1) . Three of the PI-EGI subjects had a 1-hour OGTT glucose ≥200 mg/dL (11.1 mmol/L) consistent with current Cystic Fibrosis Foundation criteria defining indeterminate glucose tolerance (PI-INDT). 6 Age, sex distribution, and BMI were comparable across the groups (Table 1) . Study participants were in stable pulmonary status, and their lung function, as represented by percent-predicted forced expiratory volume in 1 second (FEV 1 , % predicted), was similar across groups ( Table 1) . Half of the subjects were homozygous for the loss-of-function, F508del CFTR mutation. HbA 1c was higher only in the group with CFRD (P < .01 vs PI-NGT; Table 1 ).
By definition, 1-hour OGTT glucose was higher in PI-EGI compared to PI-NGT (P < .01; Table 1 ). As expected, 1-hour OGTT glucose was also higher in PI-IGT and CFRD groups compared to PI-NGT (P < .01 for all comparisons; Table 1 ). By definition 2-hour OGTT glucose was <140 mg/dL (7.8 mmol/L) in PI-EGI and in PI-NGT, but comparatively higher in PI-EGI than in PI-NGT (P < .01). Similarly, 2-hour OGTT glucose was higher in the PI-IGT and CFRD groups compared to subjects with PI-NGT (P < .01 for all comparisons; Table 1 ). Four of the eight subjects with CFRD were recent diagnoses based on 2-hour OGTT glucose ≥200 mg/dL. Of these 4 recent diagnoses, 1 had fasting hyperglycemia and 1 had been chronically treated (~5 years) with insulin administered prior to continuous overnight enteral nutrition but was not known to have daytime hyperglycemia. Four subjects had established diagnoses of CFRD; 2 were treated with the oral antidiabetic agent repaglinide, and 1 had fasting hyperglycemia and was managed with an insulin pump.
Under free-living conditions captured by CGM, progressively higher mean glucose, glucose SD, glucose CV and times spent with glucose over 140 and 180 mg/dL (10 mmol/L) were present in PI-CF with worsening OGTT-defined glucose tolerance (Table 1 ; Figure 1 ). However, PI-EGI did not demonstrate higher glucose or glucose variability than PI-NGT.
| Insulin and incretin secretion during the MMTT
During the first 30 minutes after meal ingestion, plasma glucose (AUC glu ) was higher and insulin secretion (AUC ISR ) lower only in subjects with CFRD (P < .05 vs PI-NGT for both; Table 2 ; Figure 1A ,B).
However, insulin secretion relative to the plasma glucose excursion (AUC ISR /AUC glu ) worsened across PI glucose tolerance groups and was already reduced in the PI-EGI group compared to PI-NGT (P = .04; Table 2 ). GLP-1 (AUC GLP-1 ) and GIP (AUC GIP ) secretion by 30 minutes after meal ingestion were similar across groups ( Table 2) .
Over 180 minutes, higher plasma glucose excursion became evident in PI-EGI subjects (P = .01 vs PI-NGT) and progressed in severity among those with PI-IGT and CFRD (P < .01 vs PI-NGT; Table 2 ; Figure 2A ). With the increasing plasma glucose, AUC ISR /AUC glu was lower in the PI-EGI (P < .05 vs PI-NGT), PI-IGT (P < .01 vs PI-NGT) and CFRD (P < .01 vs PI-NGT) groups and progressed in severity as glucose tolerance worsened across PI (P < .0001; Table 2 ; Figure 2B ).
GLP-1 and GIP secretion were similar across groups (Table 2 ). Fasting islet cell hormone concentrations were similar among the groups (Table 3) . Acute insulin responses (AIRs) under fasting,~230
| Glucose and islet cell hormonal responses during the GPA test
and 340 mg/dL hyperglycemic clamp conditions (AIR arg , AIR pot , and AIR max , respectively) were progressively lower with worsening OGTTdefined glucose intolerance (P < .01 for all; Table 3 ). Under hyperglycemic clamp conditions, PI-EGI had lower AIRs than PI-NGT (AIR pot :
P < .01 and AIR max : P < .05; Table 3 ), while AIR pot and AIR max were not significantly different between PI-EGI and PI-IGT (Table 3 ; Figure 2C ).
Similarly, C-peptide results were consistent with reduced β-cell secretory capacity. Acute C-peptide responses (ACR arg , ACR pot , and ACR max ) were progressively lower in PI-CF groups as glucose tolerance worsened. Under all conditions, PI-EGI had lower ACRs compared to PI-NGT (P < .05 for all comparisons; Table 3 ).
No differences in acute glucagon responses (AGR arg , AGR inh , and AGR min ) were observed across the groups ( Table 3 ).
The acute proinsulin responses during fasting (APR arg ) did not differ significantly across groups (Table 3 ). While APR pot was lower in PI-EGI compared to PI-NGT (P < .01) and progressed in severity as glucose tolerance worsened (Table 3) , during the~340 mg/dL hyperglycemic clamp, APR max was only lower by trend across the groups (P = .06; Table 3 ).
No differences in fasting proinsulin-to-C-peptide ratios or the PISR were present under fasting or~230 mg/dL hyperglycemic clamp conditions across the groups. Under the~340 mg/dL hyperglycemic clamp condition, with worsening glucose tolerance, PISR was progressively higher, and PISR was specifically higher in PI-IGT and CFRD vs PI-NGT (P < .05 for both comparisons; Table 3 ). Figure 3A ) and directly correlated with PISR under~340 mg/dL hyperglycemic clamp conditions (ρ = 0.48, P = .003; Figure 3B ). Individuals with such early glucose intolerance (PI-EGI) in the setting of CF manifest impaired mixed-meal tolerance with reduced earlyphase insulin secretion and reduced β-cell secretory capacity that related to disproportionately elevated proinsulin-to-C-peptide secretion during hyperglycemia to~340 mg/dL. Importantly, β-cell secretory capacity provides a measure of functional β-cell mass, and disproportionate proinsulin secretion reflects increased β-cell secretory demand. 21 These defects were similar to those present in individuals with PI-IGT as defined by 2-hour OGTT glucose ≥140 mg/dL (7.8 mmol/L), and were, as expected, worse in those with CFRD. Thus, the disproportionate proinsulin-to-C-peptide secretion evidences release of immature β-cell granules that can be seen with endoplasmic reticulum stress during the exposure of a reduced β-cell mass to hyperglycemia. 28 Here we show that even an only slightly elevated 1-hour glucose ≥155 mg/dL in PI-CF indicates the presence of a lower functional β-cell mass that is under increased demand for insulin secretion. We therefore suggest that the compromised β-cell function that accompanies these subtle glucose differences should be considered when targeting dietary and/or pharmacological interventions intended to reduce (1) pancreatic β-cell stress and (2) ultimately, CFRD development.
We previously reported that patients with PS-CF have similar β-cell secretory capacity as healthy control subjects with normal PISRs during hyperglycemia, while PI-CF subjects with a 1-hour OGTT glucose <200 mg/dL exhibited reduced β-cell secretory capacity, increased PISRs during hyperglycemia, and impaired early-phase insulin secretion in response to meal ingestion. 4 In that study, the 1-hour OGTT glucose was inversely correlated with measures of β-cell secretory capacity. 4 Using an expanded cohort of PI-CF subjects, here we report that using a lower 1-hour OGTT glucose cutoff of We previously reported evidence for generalized islet loss based on reductions in both β-and α-cell secretory responses during the GPA test in PI-CF compared to PS-CF subjects and healthy controls. 4 Here, we show that α-cell glucagon responses to arginine under fasting (when in fact the glucagon response is maximal) and both hyperglycemic clamp conditions are similar in all PI groups. In contrast to the increased glucagon secretion reported in type 2 diabetes, 29, 30 enhanced glucagon secretion does not contribute to the progression of glucose intolerance in PI-CF. In addition, we did not detect worsening of insulin sensitivity across the groups of PI-CF subjects. Therefore, the physiologic defect in maintaining glucose homeostasis in CF appears restricted to progressive deficiency in islet β-cell insulin secretion.
FIGURE 2
Plasma glucose (A) and insulin secretory rates (B) in response to the mixed-meal tolerance test (MMTT) in subjects with pancreatic insufficient CF (PI-CF). Impaired mixed-meal tolerance (A) and early-phase insulin secretion (B) were consistent with the oral glucose tolerance test categorization (NGT, normal glucose tolerance; EGI, early glucose intolerance; IGT, impaired glucose tolerance; CFRD, CF-related diabetes). Acute insulin responses to arginine as a function of the pre-stimulus plasma glucose concentration (C) derived from the glucose-potentiated arginine test indicate a downward shift consistent with reduced β-cell secretory capacity in PI-EGI that is similar as for PI-IGT, progressing further in CFRD, with no change in β-cell sensitivity to glucose (PG 50 ). Insulin sensitivity (D) calculated as M/I from the~230 mg/dL (13 mmol/L) glucose clamp was not different across the groups of PI subjects. In A, B, and C data are given as mean AE SE, and in D as median and interquartile range (box) and mean (open squares) and range (error bars). Normal ranges are provided as the 95% CI for data derived from healthy control subjects Abbreviations: CFRD, cystic fibrosis-related diabetes; EGI, early glucose intolerance; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; PI, pancreatic insufficient cystic fibrosis. Data are medians and interquartile ranges. *P < .05 vs PI-NGT; **P < .01 vs PI-NGT. a n = 12 for AIR arg , AGR arg , AGR pot , APR arg , PISR, fasting, PISR, 340 mg/dL (19 mmol/L).
b n = 11 for AIR max .
c n = 6 for ACR pot , AIR pot , AGR pot , APR pot .
d n = 7 for APR max .
e 1:1 conversion from pg/mL to ng/L.
FIGURE 3
Relationship between oral glucose tolerance test (OGTT) 1-hour glucose and β-cell secretory capacity (ACR max ; A) and proinsulin secretory ratio (PISR; B) during the~340 mg/dL (19 mmol/L) hyperglycemic clamp
In conclusion, impaired early-phase insulin secretion and β-cell secretory capacity are present with EGI defined by 1-hour OGTT glucose as low as 155 mg/dL. The disproportionately increased proinsulin-to-C-peptide secretion provides evidence for increased insulin secretory demand during exposure to hyperglycemia and raises concern for compounding the underlying insulin secretion defects.
Future studies should assess the clinical implications of these early islet β-cell defects and address whether dietary and/or pharmacological interventions that reduce pancreatic β-cell stress in PI-EGI may delay progression to CFRD.
